Skip to main content
. Author manuscript; available in PMC: 2015 Sep 11.
Published in final edited form as: Clin Cancer Res. 2015 Feb 27;21(11):2471–2479. doi: 10.1158/1078-0432.CCR-14-2332

Table 3.

Impact of ASI use on OS and PFS.

OS PFS
N Median
(months)		 P-Value HRa
(95% CI)		 Median
(months)		 P-Value HRa
(95% CI)
Overall Cohort (n=4736)
  ASI users
  Other anti-
  hypertensive therapy
  usersb
  Anti-hypertensive
  therapy non-users		 1487
783


2466		 26.68
18.07


16.72		 Test 8.34
6.70


6.35		 Test
0.0105


0.0026 		0.838
(0.731-0.960)

0.810
(0.707-0.929)		 0.0261


0.4226		 0.877
(0.782-0.984)

0.955
(0.855-1.068)
Overall Cohort by Type of Therapy (n=4736)
VEGF Therapy (n=3511)
  ASI users
  ASI non-users
1192
2319
31.12
20.21
<0.0001
0.737 (0.640-0.848)
10.15
8.09
0.0869
0.907 (0.812-1.014)
mTOR Therapy (n=665)
  ASI users
  ASI non-users
151
514
12.66
10.16
0.2975
0.867 (0.664-1.134)
5.46
4.05
0.5650
0.929 (0.725-1.192)
IFN-α Therapy (n=560)
  ASI users
  ASI non-users
144
416
15.54
14.82
0.2027
1.218 (0.899-1.647)
3.84
3.68
0.9084
0.984 (0.747-1.297)
Patients Receiving VEGF-Targeted and Anti-Hypertensive Therapy (n=1769)
  ASI users
  Other anti-
  hypertensive therapy
  usersb 		1192
577		 31.12
21.94		 0.0003 0.725 (0.609-0.861) 10.15
7.82		 0.0121 0.835 (0.726-0.962)
Patients Receiving VEGF-Targeted Therapy who Developed Treatment-Associated Hypertension (n=2466)
  ASI users
  ASI non-users		 982
1484		 33.19
24.64		 0.0004 0.742 (0.629-0.875) 10.92
9.05		 0.0498 0.883 (0.779-1.000)
a

HR of ASI users to comparator group from multivariate analysis, adjusted for age, sex, race, Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors, presence of baseline hypertension and the development of treatment-associated hypertension.

b

Other anti-hypertensive agents include beta-blockers, calcium-channel blockers, diuretics, and other agents.

Bolded p-values are statistically significant.

ASI = angiotensin system inhibitors, CI = confidence interval, HR = hazard ratio, IMDC = International mRCC Database Consortium, IFN-α = interferon alpha, mTOR = mammalian target of rapamycin, OS = overall survival, PFS = progression-free survival, VEGF = vascular endothelial growth factor.